摘要
目的探讨西妥昔单抗联合化疗治疗中晚期食管癌的临床观察。方法选取浙江中医药大学附属同德医院2013年2月~2016年5月收治的中晚期食管癌患者80例为研究对象,采用随机数字表法将患者分为对照组(n=40)和研究组(n=40),对照组给予氟尿嘧啶联合顺铂(FP)化疗治疗,研究组在此基础上联合西妥昔单抗治疗,比较两组患者临床疗效、肿瘤标志物水平、生存质量、生存率以及不良反应。结果研究组治疗4个周期后临床总有效率高于对照组(P<0.05)。两组患者治疗4个周期后鳞状细胞癌抗原(SCC)、癌胚抗原(CEA)均降低,且研究组低于对照组(P<0.05)。两组治疗4个周期后欧洲癌症研究组织生存质量测定(EORTC QLQ-C30)量表评分均升高,且研究组高于对照组(P<0.05)。研究组随访12、18、24个月后生存率高于对照组,但组间比较差异无统计学意义(P>0.05)。两组治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论西妥昔单抗联合化疗治疗中晚期食管癌,效果确切,可有效改善肿瘤标志物水平,改善患者生存质量,且不增加不良反应发生率,临床应用价值较高。
Objective To investigate the clinical observation of Cetuximab combined with Chemotherapy in the treatment of middle and advanced esophageal cancer.Methods Eighty patients with advanced esophageal cancer admitted to Tongde Hospital Affiliated to Zhejiang Chinese Medical University from February 2013 to May 2016 were selected as research objects.Patients were divided into control group(n=40)and study group(n=40)by random number table method.The control group was given Fluorouracil combined with cisplatin(FP)chemotherapy,and the study group was combined with Cetuximab on the basis of the conttol group.The clinical efficacy,tumor marker level,quality of life,survival rate and adverse reactions of the two groups were compared.Results The total clinical response rate of the study group was higher than that of the control group(P<0.05).After 4 cycles of treatment,SCC and CEA were decreased in both groups,and the study group were lower than those in the control group(P<0.05).EORTC QLQ-C30 scale score was increased in both groups after 4 cycles of treatment,and the group was higher than the control group(P<0.05).The survival rate of the study group was higher than that of the control group after follow-up of 12,18 and 24 months,but there were no statistically significant difference between the two groups(P>0.05).There was no statistically significant difference between the two groups in the incidence of adverse reactions during treatment(P>0.05).Conclusion Cetuximab combined with Chemotherapy in the treatment of advanced esophageal cancer has a definite effect,can effectively improve the level of tumor markers,improve the quality of life of patients,without increasing the incidence of adverse reactions,and has a high clinical application value.
作者
刘志军
何忠良
陈国兴
何雪明
LIU Zhijun;HE Zhongliang;CHEN Guoxing;HE Xueming(Department of Cardiothoracic Surgery,Tongde Hospital Affiliated to Zhejiang Chinese Medical University(Tongde Hospital of Zhejiang Province),Zhejiang Province,Hangzhou,310012,China)
出处
《中国医药导报》
CAS
2019年第23期156-159,共4页
China Medical Herald
基金
浙江省医药卫生科技计划项目(2019322843)
关键词
西妥昔单抗
化疗
中晚期
食管癌
临床疗效
Cetuximab
Chemotherapy
Middle and advanced stage
Esophageal cancer
Clinical efficacy
